Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer
Open accessThe DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index; 88 of the 108 sources its claims cite were checked for support.
Abstract
Gastric cancer (GC) is one of the most common cancers worldwide. Most patients are diagnosed at the progressive stage of the disease, and current anticancer drug advancements are still lacking. Therefore, it is crucial to find relevant biomarkers with the accurate prediction of prognoses and good predictive accuracy to select appropriate patients with GC. Recent advances in molecular profiling technologies, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, have enabled the approach of GC biology at multiple levels of omics interaction networks. Systemic biological analyses, such as computational inference of "big data" and advanced bioinformatic approaches, are emerging to identify the key molecular biomarkers of GC, which would benefit targeted therapies. This review summarizes the current status of how bioinformatics analysis contributes to biomarker discovery for prognosis and prediction of therapeutic efficacy in GC based on a search of the medical literature. We highlight emerging individual multi-omics datasets, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics, for validating putative markers. Finally, we discuss the current challenges and future perspectives to integrate multi-omics analysis for improving biomarker implementation. The practical integration of bioinformatics analysis and multi-omics datasets under complementary computational analysis is having a great impact on the search for predictive and prognostic biomarkers and may lead to an important revolution in treatment.
Overview
CoChat Summary
TL;DR
This narrative review summarizes how bioinformatics and single- or multi-omics analyses have been used to identify predictive and prognostic biomarkers in gastric cancer across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and pharmacogenomics. It argues that integrating multi-omics with computational and machine-learning methods may improve patient stratification and therapy selection, but clinical translation still requires validation, standardization, and large trials.
Key findings
- Across omics layers, many candidate signatures are reported: a six-metastasis-related gene set; 50 DEGs from 375 TCGA GC samples with 10 linked to outcome and macrophage infiltration; 39 prognostic gene signatures with COL1A1, COL1A2, and EGFR each identified three times; an 11-DMS methylation signature; an eight-MDEG signature; 110 differentially expressed miRNAs with a three-miRNA prognostic signature; 18 immune-related lncRNAs; 429 differentially expressed proteins; 24 survival-associated metabolites with 8 independent prognostic metabolites; and a 28-metabolite model with AUROC 0.832 and concordance index 0.83, in which 11 metabolites significantly discriminated prognosis.
- Pharmacogenomic and therapeutic prediction studies identified a three-gene platinum-response model (ND6, BRMS1, SRXN1) from 23 survival-related genes; in silico TCGA analysis predicted up to 15% of GC samples would benefit from currently approved targeted therapy versus 50% from FDA-approved alternative targeted therapies; proteomic subtypes from 206 pretreatment tumor samples were linked to XELOX, DOS, and anti-HER2 therapy; and four serum metabolites distinguished chemo-sensitive from chemo-resistant tumors with 82.5% sensitivity and specificity.
- Multi-omics integration remains challenging: TCGA and ACRG molecular classifications exist but clinical use is limited by intricacy, and no alternative marker set has yet outperformed them; a deep-learning autoencoder using RNA-seq, miRNA-seq, and DNA methylation identified two prognostic subgroups and outperformed PCA and similarity network fusion. Three bioinformatics-based GC clinical trials are ongoing (NCT06035250, NCT05319392, NCT05985577) and one is completed (NCT05620537).
- Microbiome analysis of 128 samples detected 5,450 phylotypes belonging to 19 phyla and 296 genera; enrichment of *Fusobacterium nucleatum* and *Prevotella* I in cancerous tissues was associated with worse survival.
Methods
- Non-systematic review based on electronic searches of PubMed and Google Scholar using keywords including “gastric cancer”, “bioinformatics analysis”, “multi-omics”, “artificial intelligence”, “machine learning”, “prognosis”, “prediction”, and “biomarker”.
- Included review articles and guidelines from 2018 to 2023 on bioinformatic approaches to GC genetic, epigenetic, transcriptomic, proteomic, and metabolic processes; only full English articles published within the last ten years were considered. Exclusions were duplicate articles, studies lacking diagnostic outcomes, case reports, correspondence, letters, and non-human research.
- No primary data collection, systematic quality appraisal, or meta-analysis was performed; the paper summarizes cited studies and tabulated biomarker examples.
Limitations
- The paper states that this is a non-systematic review and lists obstacles to clinical implementation: need for large phenotypically characterized datasets, high accuracy and reproducibility, difficulty obtaining suitable tissue samples, strict sample preparation requirements, high costs, incompatible data across databases, need to normalize patient characteristics such as age, race, and stage, and validation through comprehensive cohort studies and large-scale clinical trials; data standardization and benchmarking of integration methods are also needed.
- Evident from the text and tables: many cited biomarker studies rely on public databases and/or small cohorts (e.g., n=18, 31, 37, 48, 65 in some tables), with limited external validation, and no systematic quality appraisal or quantitative synthesis is reported.
- Evident: as a narrative review, it does not provide new experimental validation and cannot establish the clinical utility of the listed candidate markers.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
81 Valid · 4 Not valid · 12 Not checked · 12 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Ten of the fifty genes (RXRG, AGT, BCHE, UBE2QL1, PLCXD3, ADCYAP1R1, NRCAM, MAMDC2, CDH19, and GAMT) were linked with the outcome and macrophage infiltration in GC.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Supportedcites [14] Gao, 2022, Identification by Bioinformatics Analysis of Potential Key Genes Related to the Progression and Prognosis of Gastric Cancer, Front. Oncol. source
The Results (Survival Analysis) identify these exact ten genes among fifty as having prognostic significance in gastric cancer. The Results (Relationship Between Gene Expression and Immune Cell Infiltration) report that the ten genes’ expression was most closely related to macrophages, with correlations of varying strength. (LLM, conf=0.91)
plainstates an associationn = 375- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Based on 375 TCGA GC samples, 50 DEGs between GC and paired normal tissues were identified [14].”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Partly supportedcites [14] Gao, 2022, Identification by Bioinformatics Analysis of Potential Key Genes Related to the Progression and Prognosis of Gastric Cancer, Front. Oncol. sourceExperimental — accuracy not yet measured
The Data Collection section reports 375 TCGA primary cancers and 32 non-tumor tissues, and the Results report a comparison between gastric cancer and normal tissues. But Screening of Differentially Expressed Genes reports 3,213 differential genes; Intersecting Genes identifies 50 genes at the intersection with a trend-analysis module. The copy does not describe the normal tissues as paired with the cancers. No page numbers are available in our copy. (LLM, conf=0.90)
plainstates an associationn = 375- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, metabolic patterns changed before- and after surgical procedures in GC.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Supportedcites [63] Song, 2023, Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers, Metabolomics source
The Results section, “Metabolic differences before and after surgery,” explicitly states that metabolic patterns differed before and after surgery, particularly in gastric cancer (GC) subjects. It reports a comparison of plasma metabolomics from the same subjects at both time points. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Besides, highly expressed extracellular matrix proteins (THSD4, SRPX2, TGFBI, THBS1, and LAMB2) can serve as indicators to predict drug resistance.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 7. Pharmacogenomics-Based Validation of Predictive Markers of GC
What the sources say
- Supportedcites [72] Li, 2022, Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies, Nat. Commun. source
The Results section, “Proteomic subtyping of the GC cohort and their association with a therapeutic response” (page not provided), names all five proteins and reports higher expression in a chemotherapy non-sensitive group. It concludes that these extracellular matrix proteins are associated with drug resistance and could indicate chemotherapy response. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A major GC target identified in this analysis was the high frequency of PIK3CA mutation variants.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 7. Pharmacogenomics-Based Validation of Predictive Markers of GC
What the sources say
- Supportedcites [70] Hescheler, 2020, Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data, Gastric Cancer source
The Discussion describes a major gastric-cancer target identified by the analysis as the high incidence of PIK3CA mutation variants. The Results section on mutation variants identifies the relevant mutation hotspots. The citing sentence is a close paraphrase. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
48 more claims · 41 with their cited sources checked
Create a free account to see all 109 claims and to verify the 2 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 38
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
“Among the six common hub genes, TRYOBP and C1QB were negatively associated with the overall survival (OS) of the GC patients.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > References
“Identification of TYROBP and C1QB as Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
“Seventeen differential metabolites (sulfite, TG (54:2), TG (53:4), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methyl alanine, 3-hydroxysteroid, CL (63:4), PE-NMe (40:5), retinol, MG (21:0/0:0/0:0), tetradecanoic acid, tridecanoic acid, octacosanoic acid and myristate glycine)”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
“sulfite, TG (54:2), TG (53:4), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methyl alanine, 3-hydroxysteroid, CL (63:4), PE-NMe (40:5), retinol, MG (21:0/0:0/0:0), tetradecanoic acid, tridecanoic acid, octacosanoic acid and myristate glycine”
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Gastric cancer (GC) is a common cancer type, with more than one million new cases each year [1].”
BackgroundWGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174 · cited 1×
“Transcriptomes denote all RNA molecules created in a cell from the genome under certain pathological situations [29,30].”
BackgroundSTRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · cited 1×
“…interaction (PPI) networks and weighted gene co-expression network analysis (WGCNA) based on the RNA sequencing and microarray data have been revealed to establish potent organized biological strategies for mining the functional gene modules and detecting novel prognostic biomarkers [11,12].”
MethodBang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · cited 1×
“Despite these advances in knowledge only one oncogenic driver-based therapy (Her2-directed treatment with trastuzumab) has shown acceptable survival benefit [5].”
BackgroundComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · cited 1×
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
BackgroundNomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292 · cited 1×
“The nomogram has been broadly utilized as a predictive method in oncology for a decade [23].”
MethodMolecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3850 · Cited by 2,223 · cited 1×
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
BackgroundSimilarity network fusion for aggregating data types on a genomic scale
Wang, B., Mezlini, A. M., Demir, F., Fiume, M., Tu, Z., Brudno, M., Haibe-Kains, B., & Goldenberg, A. (2014) · Nature Methods · doi:10.1038/nmeth.2810 · Cited by 2,036 · cited 1×
“…[97], iClusterPlus [98], Patient-specific data fusion (PSDF) [99]), network and pathway integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101], MultiGSEA [102], multi-omics gene-set analysis (MOGSA) [103], Cytoscape [104]), fusion-based integration (e.g., Protein…”
BackgroundThe NIH Roadmap Epigenomics Mapping Consortium
Bernstein, B. E., Stamatoyannopoulos, J. A., Costello, J. F., Ren, B., Milosavljevic, A., Meissner, A., Kellis, M., Marra, M. A., Beaudet, A. L., Ecker, J. R., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1045 · Cited by 1,892 · cited 1×
“Similar to genomics, an increasing number of evidence suggests that epigenetic modifications, including DNA methylation of CpG islands, post-translational modifications of histones, and nucleosome positioning, are also comprised in the GC initiation, progression, and chemo-resistance [21].”
BackgroundMulti-omics Data Integration, Interpretation, and Its Application
Subramanian, I., Verma, S., Kumar, S., Jere, A., & Anamika, K. (2020) · Bioinformatics and Biology Insights · doi:10.1177/1177932219899051 · Cited by 1,609 · cited 2×
“…(e.g., Perturbation clustering for data integration and disease subtyping(PINSPlus) [106], Neighborhood-based multi-omics clustering (NEMO) [107]), and other multivariate approaches (e.g., mixOMICS [108], moCluster [109], Integrative nonnegative matrix factorization (NMF) [110]) [111,112].”
BackgroundLowe, R., Shirley, N., Bleackley, M., Dolan, S., & Shafee, T. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005457 · Cited by 1,176 · cited 1×
“Recently, transcriptomics has remarkably progressed in molecular genetics [28].”
BackgroundHelicobacter pylori: gastric cancer and beyond
Polk, D. B., & Peek, R. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2857 · Cited by 1,158 · cited 1×
“As a standout example, Helicobacter pylori infection is one of GC’s most important risk factors [95].”
BackgroundWang, K., Yuen, S. T., Xu, J., Lee, S. P., Yan, H. H. N., Shi, S. T., Siu, H. C., Deng, S., Chu, K. M., Law, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2983 · Cited by 1,045 · cited 1×
“Other important mutations in GC involve the ARID1A , PIK3CA , CCNE1, CLDN18-ARHGAP26, and BRCA2 genes [4].”
BackgroundNext-generation sequencing technologies: An overview
Hu, T., Chitnis, N., Monos, D., & Dinh, A. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.02.012 · Cited by 949
Vaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D., & Stuart, J. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq182 · Cited by 786 · cited 1×
“…be divided into categories, such as Bayesian integration (e.g., Pathway Recognition Algorithm using Data Integration on Genomic Models (PARADIGM) [97], iClusterPlus [98], Patient-specific data fusion (PSDF) [99]), network and pathway integration (e.g., Similarity network fusion (SNF) [100],…”
BackgroundMetabolomics: an emerging but powerful tool for precision medicine
Clish, C. B. (2015) · Molecular Case Studies · doi:10.1101/mcs.a000588 · Cited by 708
Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.36 · Cited by 594 · cited 1×
“Although recent developments in endoscopy, imaging, surgical procedures, and the use of anti-cancer drugs have somewhat prolonged the overall outcome of GC patients, the 5-year survival of patients with advanced GC remains 30%, mainly due to the lack of efficient therapies [2].”
BackgroundCullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578 · cited 1×
“The microbiome has been associated with regulating various physiological processes in human diseases, including cancer, and this connection is attracting increasing attention [92].”
BackgroundLong Noncoding RNA in Cancer: Wiring Signaling Circuitry
Lin, C., & Yang, L. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.008 · Cited by 488 · cited 1×
“Growing evidence has shown that long non-coding RNAs (lncRNAs), with a length of more than 200 nucleotides, can manage cancer development and the alterations of variable genes [39].”
BackgroundPattern discovery and cancer gene identification in integrated cancer genomic data
Mo, Q., Wang, S., Seshan, V. E., Olshen, A. B., Schultz, N., Sander, C., Powers, R. S., Ladanyi, M., & Shen, R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208949110 · Cited by 474 · cited 1×
“…such as Bayesian integration (e.g., Pathway Recognition Algorithm using Data Integration on Genomic Models (PARADIGM) [97], iClusterPlus [98], Patient-specific data fusion (PSDF) [99]), network and pathway integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101],…”
Cancer and the gut microbiota: An unexpected link
Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465 · cited 1×
“Among all tumors, GC is arguably the most intensely affected by gut bacteria owing to their spatial proximity, and their associations with the gut microbiome have been intensively investigated [93,94].”
BackgroundHost–microbiota maladaptation in colorectal cancer
Janney, A., Powrie, F., & Mann, E. H. (2020) · Nature · doi:10.1038/s41586-020-2729-3 · Cited by 445 · cited 1×
“Among all tumors, GC is arguably the most intensely affected by gut bacteria owing to their spatial proximity, and their associations with the gut microbiome have been intensively investigated [93,94].”
BackgroundThe complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs
Jacquier, A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2683 · Cited by 429
Integrated Omics of Metastatic Colorectal Cancer
Li, C., Sun, Y.-D., Yu, G.-Y., Cui, J.-R., Lou, Z., Zhang, H., Huang, Y., Bai, C.-G., Deng, L.-L., Liu, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.002 · Cited by 297 · cited 1×
“To diagnose differentially expressed genes (DEGs) associated with GC, databases such as The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) are frequently used [10].”
Yang, Z., & Michailidis, G. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv544 · Cited by 295 · cited 1×
“…(e.g., Perturbation clustering for data integration and disease subtyping(PINSPlus) [106], Neighborhood-based multi-omics clustering (NEMO) [107]), and other multivariate approaches (e.g., mixOMICS [108], moCluster [109], Integrative nonnegative matrix factorization (NMF) [110]) [111,112].”
BackgroundHorak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0126 · Cited by 290 · cited 1×
“To select efficient drugs, recent clinical trials have focused on multi-omics profiling of patients with cancer by analyzing genome-wide data, including data from DNA sequencing, gene expression profiling, and copy number profiling [66].”
BackgroundEpigenetic alterations in cancer
Nirmaladevi, R. (2020) · Frontiers in Bioscience · doi:10.2741/4847 · Cited by 289
NEMO: cancer subtyping by integration of partial multi-omic data
Rappoport, N., & Shamir, R. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz058 · Cited by 286 · cited 1×
“…(e.g., Perturbation clustering for data integration and disease subtyping(PINSPlus) [106], Neighborhood-based multi-omics clustering (NEMO) [107]), and other multivariate approaches (e.g., mixOMICS [108], moCluster [109], Integrative nonnegative matrix factorization (NMF) [110]) [111,112].”
BackgroundIntegrated Multi-Omics Analyses in Oncology: A Review of Machine Learning Methods and Tools
Nicora, G., Vitali, F., Dagliati, A., Geifman, N., & Bellazzi, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01030 · Cited by 284
Single-cell sequencing techniques from individual to multiomics analyses
Kashima, Y., Sakamoto, Y., Kaneko, K., Seki, M., Suzuki, Y., & Suzuki, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00499-2 · Cited by 270 · cited 1×
“Although bulk RNA-seq analyzes only the mean transcript expression in a cell population, single-cell RNA sequencing (scRNA-seq) evaluates the transcriptomic condition of specific populations of single cells [32].”
BackgroundComparing Bioinformatic Gene Expression Profiling Methods: Microarray and RNA-Seq
Mantione, K. J., Kream, R. M., Kuzelova, H., Ptacek, R., Raboch, J., Samuel, J. M., & Stefano, G. B. (2014) · Medical Science Monitor Basic Research · doi:10.12659/msmbr.892101 · Cited by 264 · cited 1×
“Transcription is the method of copying a segment of DNA into RNA and reveals an outline of the activity of the cells [27].”
MethodBig data in basic and translational cancer research
Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254 · cited 1×
“…has generated the concept of “big data” in cancer, the analysis of which necessitates large computational resources and bioinformatic algorithms [7]. large computational technology, a comprehensive understanding With the interpretation of bioinformatics technology, a comprehensive understanding…”
BackgroundMorganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Duso, B. A., & Curigliano, G. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-24100-1_2 · Cited by 246 · cited 1×
“The capacity to predict the efficacy of a patient with cancer on a particular treatment regimen is the elaborate goal of precision oncology [67].”
BackgroundMetabolomic machine learning predictor for diagnosis and prognosis of gastric cancer
Chen, Y., Wang, B., Zhao, Y., Shao, X., Wang, M., Ma, F., Yang, L., Nie, M., Jin, P., Yao, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46043-y · Cited by 244 · cited 1×
“A more recent study that employed LC–MS-based targeted metabolomics to illustrate the global metabolomic profiling of large cohorts analyzed plasma samples from GC patients utilizing machine learning [62].”
MethodCancer proteogenomics: current impact and future prospects
Mani, D. R., Krug, K., Zhang, B., Satpathy, S., Clauser, K. R., Ding, L., Ellis, M., Gillette, M. A., & Carr, S. A. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00446-5 · Cited by 229 · cited 1×
“Recent advances in proteomics through the maturation of several MS techniques have enabled the introduction of proteogenomic approaches that can integrate genomic data with proteomics and information on post-translational modifications [89].”
BackgroundTargeting Cancer Metabolism: Dietary and Pharmacologic Interventions
Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0615 · Cited by 202 · cited 1×
“Commonly, cancer metabolism has a significant role in the tumorigenesis, progression, as well as drug resistance of cancer [55].”
BackgroundCharacterizing DNA methylation alterations from The Cancer Genome Atlas
Weisenberger, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69740 · Cited by 200 · cited 1×
“DNA methylation alterations are essential to all phases of cancer genomics, and hypomethylation has been revealed to be pivotal in cancer progression [22].”
BackgroundIntegrated Analysis of lncRNA–Mediated ceRNA Network in Lung Adenocarcinoma
Wu, X., Sui, Z., Zhang, H., Wang, Y., & Yu, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554759 · Cited by 198 · cited 1×
“Competitive endogenous RNAs (ceRNA) is a novel regulatory mechanism that has been found to be involved in a variety of progression processes in cancer [116].”
BackgroundApplications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179 · cited 1×
“Metabolomics can amplify small alterations in the genome, transcriptome, and proteome, which indicate the termination of gene activities and changes in individuals [54].”
BackgroundCytoscape.js 2023 update: a graph theory library for visualization and analysis
Franz, M., Lopes, C. T., Fong, D., Kucera, M., Cheung, M., Siper, M. C., Huck, G., Dong, Y., Sumer, O., & Bader, G. D. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad031 · Cited by 177 · cited 1×
“…integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101], MultiGSEA [102], multi-omics gene-set analysis (MOGSA) [103], Cytoscape [104]), fusion-based integration (e.g., Protein fusion analysis (PFS) [105]), similarity-based integration (e.g., Perturbation clustering for data…”
BackgroundA guide to multi-omics data collection and integration for translational medicine
Athieniti, E., & Spyrou, G. M. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.050 · Cited by 174 · cited 2×
“…(e.g., Perturbation clustering for data integration and disease subtyping(PINSPlus) [106], Neighborhood-based multi-omics clustering (NEMO) [107]), and other multivariate approaches (e.g., mixOMICS [108], moCluster [109], Integrative nonnegative matrix factorization (NMF) [110]) [111,112].”
BackgroundmultiGSEA: a GSEA-based pathway enrichment analysis for multi-omics data
(2020) · doi:10.1186/s12859-020-03910-x · Cited by 170 · cited 1×
“…data fusion (PSDF) [99]), network and pathway integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101], MultiGSEA [102], multi-omics gene-set analysis (MOGSA) [103], Cytoscape [104]), fusion-based integration (e.g., Protein fusion analysis (PFS) [105]),…”
BackgroundPaintOmics 3: a web resource for the pathway analysis and visualization of multi-omics data
(2018) · doi:10.1093/nar/gky466 · Cited by 169 · cited 1×
“…[98], Patient-specific data fusion (PSDF) [99]), network and pathway integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101], MultiGSEA [102], multi-omics gene-set analysis (MOGSA) [103], Cytoscape [104]), fusion-based integration (e.g., Protein fusion analysis (PFS)…”
BackgroundmoCluster: Identifying Joint Patterns Across Multiple Omics Data Sets
Meng, C., Helm, D., Frejno, M., & Kuster, B. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00824 · Cited by 140 · cited 1×
“…(e.g., Perturbation clustering for data integration and disease subtyping(PINSPlus) [106], Neighborhood-based multi-omics clustering (NEMO) [107]), and other multivariate approaches (e.g., mixOMICS [108], moCluster [109], Integrative nonnegative matrix factorization (NMF) [110]) [111,112].”
BackgroundYang, H., Zou, X., Yang, S., Zhang, A., Li, N., & Ma, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1149989 · Cited by 139 · cited 1×
“Another study has described that six lactylation-related prognostic gene models in GC tissues were established using the GSEA, TCGA, and GEO databases [71].”
MethodPINSPlus: a tool for tumor subtype discovery in integrated genomic data
Nguyen, H., Shrestha, S., Draghici, S., & Nguyen, T. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty1049 · Cited by 139 · cited 1×
“…fusion analysis (PFS) [105]), similarity-based integration (e.g., Perturbation clustering for data integration and disease subtyping(PINSPlus) [106], Neighborhood-based multi-omics clustering (NEMO) [107]), and other multivariate approaches (e.g., mixOMICS [108], moCluster [109], Integrative…”
MethodDevelopment and validation of a prognostic and predictive 32-gene signature for gastric cancer
Cheong, J., Wang, S. C., Park, S., Porembka, M. R., Christie, A. L., Kim, H., Kim, H. S., Zhu, H., Hyung, W. J., Noh, S. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28437-y · Cited by 126
MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer
Jiang, C., Chen, X., Alattar, M., Wei, J., & Liu, H. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.19 · Cited by 111 · cited 1×
“However, accumulating evidence has found that ncRNAs contribute to the initiation and progression of GC and can act as important biomarkers in prognosis [35,36].”
BackgroundPatient-specific data fusion defines prognostic cancer subtypes
Yuan, Y., Savage, R. S., & Markowetz, F. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002227 · Cited by 97 · cited 1×
“…Pathway Recognition Algorithm using Data Integration on Genomic Models (PARADIGM) [97], iClusterPlus [98], Patient-specific data fusion (PSDF) [99]), network and pathway integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101], MultiGSEA [102], multi-omics gene-set analysis…”
MethodPattern fusion analysis by adaptive alignment of multiple heterogeneous omics data
Shi, Q., Zhang, C., Peng, M., Yu, X., Zeng, T., Liu, J., & Chen, L. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx176 · Cited by 89 · cited 1×
“…MultiGSEA [102], multi-omics gene-set analysis (MOGSA) [103], Cytoscape [104]), fusion-based integration (e.g., Protein fusion analysis (PFS) [105]), similarity-based integration (e.g., Perturbation clustering for data integration and disease subtyping(PINSPlus) [106], Neighborhood-based…”
MethodProteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD
Hedl, T. J., San Gil, R., Cheng, F., Rayner, S. L., Davidson, J. M., De Luca, A., Villalva, M. D., Ecroyd, H., Walker, A. K., & Lee, A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00548 · Cited by 87 · cited 1×
“Recent technologies allow to prediction of protein expression change, which may mediate the cellular biological processes [46].”
BackgroundChen, J., Liu, K., Luo, Y., Kang, M., Wang, J., Chen, G., Qi, J., Wu, W., Wang, B., Han, Y., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.008 · Cited by 84 · cited 1×
“A study using an immune-targeted single-cell profiling strategy examined the role of tumor immune microenvironment (TIME) in the progression of gastric signet ring cell carcinoma (GSRCC) [33].”
BackgroundBai, Y., Wei, C., Zhong, Y., Zhang, Y., Long, J., Huang, S., Xie, F., Tian, Y., Wang, X., & Zhao, H. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41587 · Cited by 83 · cited 1×
“…study using a risk score and OS nomogram for predicting the prognosis of GC patients identified six DNA methylation-driven DEGs ( PODN , MYO1A , NPY , MICU3 , TUBB6 , and RHOJ ) as prognostic genes using a least absolute shrinkage and selection operator (LASSO) logistic regression model [24].”
MethodLi, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80 · cited 2×
“Beyond these studies, many researchers have sought other surrogate molecular classifications of GC to detect biomarkers and validate therapeutic prediction based on various analyses, including epigenome, proteome, metabolome, immunity, and tumor mutational burden [56,72,79–87].”
BackgroundMethodIdentification of functional lncRNAs in gastric cancer by integrative analysis of GEO and TCGA data
Zhang, X., Zhang, W., Jiang, Y., Liu, K., Ran, L., & Song, F. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29058 · Cited by 78 · cited 1×
“The integrative analysis of GEO and TCGA data reported that three lncRNAs (UCA1, HOTTIP, and HMGA1P4) may be involved in the development, and their prospective activities may be related to the prognosis of GC [42].”
Gastric Cancer Genomics: Advances and Future Directions
Katona, B. W., & Rustgi, A. K. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.003 · Cited by 78 · cited 1×
“So far, comprehensive molecular analysis has identified many molecular alterations and dysregulated pathways in GC. Mutations in the TP53 and CDH1 /RHOA genes are well-known [3].”
BackgroundMOGSA: Integrative Single Sample Gene-set Analysis of Multiple Omics Data
(2019) · doi:10.1074/mcp.tir118.001251 · Cited by 78 · cited 1×
“…and pathway integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101], MultiGSEA [102], multi-omics gene-set analysis (MOGSA) [103], Cytoscape [104]), fusion-based integration (e.g., Protein fusion analysis (PFS) [105]), similarity-based integration (e.g., Perturbation…”
BackgroundLin, Y., Pan, X., Zhao, L., Yang, C., Zhang, Z., Wang, B., Gao, Z., Jiang, K., Ye, Y., Wang, S., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00249-x · Cited by 67
Lehr, K., Nikitina, D., Vilchez-Vargas, R., Steponaitiene, R., Thon, C., Skieceviciene, J., Schanze, D., Zenker, M., Malfertheiner, P., Kupcinskas, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31740-3 · Cited by 54 · cited 1×
“A recent study characterized the mucosal microbiome composition in paired cancerous and adjacent normal tissues and found significant correlations with the prognosis of GC patients [96].”
BackgroundProteomic cancer biomarkers from discovery to approval: it’s worth the effort
Li, D., & Chan, D. W. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.897614 · Cited by 54 · cited 1×
“The developments in knowledge and technologies of high-throughput mass spectroscopy (MS) provoke the identification of effective biomarkers for GC [47].”
BackgroundJiang, J., Ding, Y., Wu, M., Lyu, X., Wang, H., Chen, Y., Wang, H., & Teng, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01765 · Cited by 52 · cited 1×
“Both genes were also correlated with the CD8 + T cells, CD4 + T cells, and macrophages using an immune analysis based on the TCG-STAD [17].”
MethodShi, W., Wang, Y., Xu, C., Li, Y., Ge, S., Bai, B., Zhang, K., Wang, Y., Zheng, N., Wang, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35797-6 · Cited by 50 · cited 1×
“For instance, there has been deep attention to the comprehensive characterization of the divergent mechanisms of diffuse-GC and intestinal-GC [90].”
BackgroundComprehensive pharmacogenomic characterization of gastric cancer
Sa, J. K., Hong, J. Y., Lee, I.-K., Kim, J.-S., Sim, M.-H., Kim, H. J., An, J. Y., Sohn, T. S., Lee, J. H., Bae, J. M., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-0717-8 · Cited by 46 · cited 1×
“…the effect of epidermal growth factor receptor inhibitors for signet-ring cells, vascular endothelial growth factor receptor inhibitors for diffuse-type tumors, PARP inhibitors for tumors with BRCA2 mutation, WNT inhibitors for ALK-mutant tumors, and AKT blockade for PIK3CA-E542K mutation [68].”
BackgroundWang, H., Ding, Y., Chen, Y., Jiang, J., Chen, Y., Lu, J., Kong, M., Mo, F., Huang, Y., Zhao, W., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01201-9 · Cited by 46 · cited 1×
“Beyond these studies, many researchers have sought other surrogate molecular classifications of GC to detect biomarkers and validate therapeutic prediction based on various analyses, including epigenome, proteome, metabolome, immunity, and tumor mutational burden [56,72,79–87].”
BackgroundDiscovering Biomarkers in Peritoneal Metastasis of Gastric Cancer by Metabolomics
Pan, G., Ma, Y., Suo, J., Li, W., Zhang, Y., Qin, S., Jiao, Y., Zhang, S., Li, S., Kong, Y., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s245663 · Cited by 45 · cited 1×
“They divided the patients into two groups depending on the existence of peritoneal metastasis, serosal invasion, and CEA mRNA [59].”
BackgroundChivu-Economescu, M., Necula, L. G., Matei, L., Dragu, D., Bleotu, C., Sorop, A., Herlea, V., Dima, S., Popescu, I., & Diaconu, C. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063214 · Cited by 42 · cited 2×
“[19] Abbreviations: GC, gastric cancer; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; GO, gene oncology; KEGG, The Kyoto Encyclopedia of Genes and Genomes; WGCNA, weighted correlation network analysis; TIMER, Tumor Immune Estimation Resource; PPI, protein–protein interaction; N.A.,…”
BackgroundSASADA, S., MIYATA, Y., TSUTANI, Y., TSUYAMA, N., MASUJIMA, T., HIHARA, J., & OKADA, M. (2013) · Oncology Reports · doi:10.3892/or.2012.2182 · Cited by 41
Zhang, C., Zhang, C.-D., Ma, M.-H., & Dai, D.-Q. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i11.1206 · Cited by 40 · cited 2×
“The multivariate analysis showed that the T stage and the three-DEM signature were all independent factors in predicting the prognosis of patients with GC [37].”
MethodWhole Genome Messenger RNA Profiling Identifies a Novel Signature to Predict Gastric Cancer Survival
Dai, J. M., Li, Z., Zhang, Y., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000004 · Cited by 40
Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
del Arco, C. D., Fernández‐Aceñero, M. J., & Ortega, L. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052649 · Cited by 39 · cited 1×
“The application of novel molecular techniques beyond NGS, such as third-generation and single-cell sequencing, and the classification of patients in clinical trials according to molecular alterations may eventually lead to a consensus molecular classification [88].”
Sun, H., Huang, X., Wang, Z., Zhang, G., Mei, Y., Wang, Y., Nie, Z., & Wang, S. (2019) · Journal of Cancer · doi:10.7150/jca.35939 · Cited by 38 · cited 1×
“Lipid metabolism deregulation is one of the most familiar metabolic alterations in cancer [60].”
BackgroundFurukawa, K., Hatakeyama, K., Terashima, M., Nagashima, T., Urakami, K., Ohshima, K., Notsu, A., Sugino, T., Yagi, T., Fujiya, K., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01242-0 · Cited by 32
A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer
Liu, L., Pang, H., He, Q., Pan, B., Sun, X., Shan, J., Wu, L., Wu, K., Yao, X., & Guo, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02007-6 · Cited by 29 · cited 1×
“A recent study using a prognostic risk model by multivariate Cox regression analysis in GEO datasets GSE15459 investigated potential prognostic genes [18].”
MethodMultivariate Analysis with the R Package mixOmics
Welham, Z., Dejean, S., & Cao, K. L. (2012) · Methods in molecular biology · doi:10.1007/978-1-0716-1967-4_15 · Cited by 26 · cited 1×
“…(e.g., Perturbation clustering for data integration and disease subtyping(PINSPlus) [106], Neighborhood-based multi-omics clustering (NEMO) [107]), and other multivariate approaches (e.g., mixOMICS [108], moCluster [109], Integrative nonnegative matrix factorization (NMF) [110]) [111,112].”
BackgroundWang, X., Yan, S., Dai, W., Liu, X., Zhang, W., & Wang, J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25294 · Cited by 26 · cited 1×
“Previous studies have indicated that metabolomics analysis in GC may offer a useful approach to chemosensitivity prediction [73–75].”
BackgroundSong, G., Wang, L., Tang, J., Li, H., Pang, S., Li, Y., Liu, L., & Hu, J. (2023) · Metabolomics · doi:10.1007/s11306-023-02002-0 · Cited by 25 · cited 1×
“A study by Song and colleagues attempted to detect metabolic features for gastrointestinal cancer prognostic assessment [63].”
BackgroundKim, K., Yang, J., Kwack, S. J., Kim, H. S., Ryu, D. H., Kim, Y., Bae, J. Y., Lim, D. S., Choi, S. M., Kwon, M. J., et al. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2778 · Cited by 25 · cited 1×
“Previous studies have indicated that metabolomics analysis in GC may offer a useful approach to chemosensitivity prediction [73–75].”
BackgroundGhandikota, S. K., Hershey, G. K. K., & Baye, T. M. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty182 · Cited by 23 · cited 1×
“In addition, there is a varied array of platforms that facilitate visualization and clarification of multi-omics data, involving GENEASE [113], CGDV [114], and SLIDE [115], which provide ease of visualization and interpretation of large biological data sets.”
BackgroundPrognostic Roles of ceRNA Network-Based Signatures in Gastrointestinal Cancers
Qi, X., Chen, X., Zhao, Y., Chen, J., Niu, B., & Shen, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.921194 · Cited by 22 · cited 1×
“The competitive endogenous RNAs (ceRNA) hypothesis declares that as ceRNAs, some RNAs can mediate the expression of downstream mRNA by linking distributed miRNAs [41].”
BackgroundProteomic Identification of a Gastric Tumor ECM Signature Associated With Cancer Progression
Moreira, A. M., Ferreira, R. M., Carneiro, P., Figueiredo, J., Osório, H., Barbosa, J., Preto, J., Pinto-do-Ó, P., Carneiro, F., & Seruca, R. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.818552 · Cited by 21 · cited 2×
“[50] Abbreviations: GC, gastric cancer; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; EGA, European genome-phenome archive; MS, mass spectrometry; KEGG, The Kyoto Encyclopedia of Genes and Genomes; PPI, protein–protein interaction; HSP, heat shock protein; TFF, trefoil factor; MAPK,…”
BackgroundAlterations in the gastric microbiota and metabolites in gastric cancer: An update review
Lei, C., Gong, D., Zhuang, B., & Zhang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960281 · Cited by 20 · cited 1×
“Over the past few years, with the advancement of metabolomics technology, previous studies have examined the application of metabolomics to identify novel biomarkers and uncover prediction biomarkers for prognosis in GC [57] (Table 5).”
BackgroundPrognostic Implication of Plasma Metabolites in Gastric Cancer
Cao, K., Lyu, Y., Chen, J., He, C., Lyu, X., Zhang, Y., Chen, L., Jiang, Y., Xiang, J., Liu, B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612774 · Cited by 16 · cited 1×
“A study screening GC survival-associated metabolites identified 24 metabolites by using Kaplan–Meier survival analysis [58].”
MethodmGWAS-Explorer: Linking SNPs, Genes, Metabolites, and Diseases for Functional Insights
Chang, L., Zhou, G., Ou, H., & Xia, J. (2022) · Metabolites · doi:10.3390/metabo12060526 · Cited by 15 · cited 1×
“Studies integrating metabolomics and genetics analyses, known as metabolite GWAS (mGWAS), enable the examination of correlations between a variety of gene alterations and metabolites and a valuable understanding of the genetic control of metabolite levels [64].”
BackgroundWeng, S., Li, M., Deng, J., Xu, H., Ren, Y., Zhou, Z., Wang, L., Zhang, Y., Xing, Z., Li, L., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01478-w · Cited by 15 · cited 1×
“Beyond these studies, many researchers have sought other surrogate molecular classifications of GC to detect biomarkers and validate therapeutic prediction based on various analyses, including epigenome, proteome, metabolome, immunity, and tumor mutational burden [56,72,79–87].”
BackgroundHu, B.-L., Xie, M.-Z., Li, K.-Z., Li, J.-L., Gui, Y.-C., & Xu, J.-W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109159 · Cited by 15 · cited 1×
“They also evaluated the expression of the six distant-metastasis gens in the GC tissue sample, and the reliability of the prognostic value was shown [13].”
BackgroundZheng, G.-L., Zhang, G.-J., Zhao, Y., & Zheng, Z.-C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.901182 · Cited by 15 · cited 1×
“A recent study established a prognostic risk model [48].”
BackgroundChen, S., Zang, Y., Xu, B., Lu, B., Ma, R., Miao, P., & Chen, B. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5844846 · Cited by 15 · cited 2×
“Membership in one subgroup was deemed to be a risk factor using the univariate and multivariate Cox-PH model, and the model based on the autoencoder-integrating multi-omics analysis showed more suitable performance as a prognostic marker than other clinicopathological features [117].”
BackgroundMethodRecognition of DNA Methylation Molecular Features for Diagnosis and Prognosis in Gastric Cancer
Liu, D., Li, L., Wang, L., Wang, C., Hu, X., Jiang, Q., Wang, X., Xue, G., Liu, Y., & Xue, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.758926 · Cited by 14 · cited 3×
“[25] Abbreviations: GC, gastric cancer; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; GO, gene oncology; KEGG, The Kyoto Encyclopedia of Genes and Genomes; PPI, protein-protein interaction; DMS, differential methylation site.”
BackgroundMethodInfluentialLi, X., Duan, Y., & Hao, Y. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00916-z · Cited by 14 · cited 1×
“Three genes ( COL1A1 , COL1A2, EGFR) were identified three times, suggesting that they have superior potential in GC prognosis and may provide a theoretic foundation for improving treatment strategies [15].”
BackgroundAssessing the Value of Next-Generation Sequencing Technologies: An Introduction
Phillips, K. A. (2018) · Value in Health · doi:10.1016/j.jval.2018.06.012 · Cited by 14 · cited 2×
“…which researchers can decipher the various mechanisms responsible for the heterogeneity of GC [8]. genetic, epigenetic, proteomic, transcriptomic metabolic processes has been developed as a framework with which researchers decipher the various mechanisms responsible for the heterogeneity of GC [8].”
BackgroundLi, L.-D., & Ma, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-00410-7 · Cited by 13
Zhang, Y., Liu, W., Feng, W., Wang, X., Lei, T., Chen, Z., & Song, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.816249 · Cited by 13 · cited 1×
“These 14 genes were significantly enriched in metabolic pathways, suggesting that metabolic genes have a pivotal role in GC [34].”
BackgroundGao, W., & Yang, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.881015 · Cited by 13
Wang, D., Li, W., Yin, L., Du, Y., Zhang, S., & Suo, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.11350 · Cited by 12 · cited 2×
“Recently, a study examined the role of metabolite profiles in sensitivity to neoadjuvant chemotherapy in GC [76].”
BackgroundHescheler, D. A., Plum, P. S., Zander, T., Quaas, A., Korenkov, M., Gassa, A., Michel, M., Bruns, C. J., & Alakus, H. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01045-9 · Cited by 12 · cited 1×
“Other drugs identified here for therapeutic options are sorafenib (16% of TCGA GC patients), cobozantinib, and regorafenib [70].”
BackgroundCancer functional states-based molecular subtypes of gastric cancer
Zhou, Q., Yuan, Y., Hao, L., Li, X., Liu, Z., Gan, J., Yue, Z., Wu, J.-P., Sheng, J., & Lin, X. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03921-1 · Cited by 12
Prediction of Two Molecular Subtypes of Gastric Cancer Based on Immune Signature
Wu, D., Feng, M., Shen, H., Shen, X., Hu, J., Liu, J., Yang, Y., Li, Y., Yang, M., Wang, W., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.793494 · Cited by 11
Efficacy of Analytical Technologies in Metabolomics Studies of the Gastrointestinal Cancers
Aftabı, Y., Soleymani, J., & Jouyban, A. (2021) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2021.1901646 · Cited by 10 · cited 2×
“Beyond these studies, many researchers have sought other surrogate molecular classifications of GC to detect biomarkers and validate therapeutic prediction based on various analyses, including epigenome, proteome, metabolome, immunity, and tumor mutational burden [56,72,79–87].”
BackgroundPrediction of platinum‐resistance patients of gastric cancer using bioinformatics
Pan, J., Xiang, Z., Dai, Q., Wang, Z., Liu, B., & Li, C. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28621 · Cited by 10 · cited 1×
“A study proposed to build a predictive model to guess the susceptibility to platinum of GC patients to excuse patients from unnecessary exposure to toxicity [69].”
BackgroundMetabolism-associated molecular classification of gastric adenocarcinoma
Ye, Y., Yang, W., Ruan, X., Xu, L., Cheng, W., Zhao, M., Wang, X., Chen, X., Cai, D., Li, G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1024985 · Cited by 10
Zhao, X., Xia, X., Wang, X., Bai, M., Zhan, D., & Shu, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847706 · Cited by 10 · cited 1×
“Meanwhile, patients with poor outcomes are enriched in ECM-related pathways [52].”
BackgroundLiao, T., Lu, Y., Li, W., Wang, K., Zhang, Y., Luo, Z., Ju, Y., & Ouyang, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.794621 · Cited by 10 · cited 2×
“[43] Abbreviations: GC, gastric cancer; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; scRNA-seq, single-cell RNA sequencing; GSRCC, gastric signet ring cell carcinoma; TIME, tumor immune microenvironment; TIMER, Tumor Immune Estimation Resource; GSEA, gene set enrichment analysis;…”
BackgroundSantos, E. C., Binato, R., Fernandes, P. V., Ferreira, M. A., & Abdelhay, E. (2022) · Cancer Biomarkers · doi:10.3233/cbm-203225 · Cited by 9 · cited 2×
“In addition, among the 20 hub proteins detected, IST1, VAT1, ALYREF, and HEXB were closely related to worse survival [51].”
BackgroundSLIDE – a web-based tool for interactive visualization of large-scale – omics data
Ghosh, S., Datta, A., Tan, K. S., & Choi, H. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty534 · Cited by 9 · cited 1×
“In addition, there is a varied array of platforms that facilitate visualization and clarification of multi-omics data, involving GENEASE [113], CGDV [114], and SLIDE [115], which provide ease of visualization and interpretation of large biological data sets.”
BackgroundFunctional Proteomic Profiling Analysis in Four Major Types of Gastrointestinal Cancers
Wang, Y., Gao, X., & Wang, J. (2023) · Biomolecules · doi:10.3390/biom13040701 · Cited by 9 · cited 1×
“Likewise, a study characterized by RPPA-based functional proteomic data identified the functional proteome signatures ( MYH11 , CD20 , CHK1_pS345 , AR , PR, HER3 , MYH11 , and SMAD1 ), suggesting that these candidate protein markers can serve as potential prognostic biomarkers in GC [49].”
BackgroundCGDV: a webtool for circular visualization of genomics and transcriptomics data
Jha, V., Singh, G., Kumar, S., Sonawane, A. D., Jere, A., & Anamika, K. (2017) · BMC Genomics · doi:10.1186/s12864-017-4169-5 · Cited by 9 · cited 1×
“In addition, there is a varied array of platforms that facilitate visualization and clarification of multi-omics data, involving GENEASE [113], CGDV [114], and SLIDE [115], which provide ease of visualization and interpretation of large biological data sets.”
BackgroundQu, T., Zhang, S., Yang, S., Li, S., & Wang, D. (2024) · BMC Cancer · doi:10.1186/s12885-023-11786-2 · Cited by 8 · cited 1×
“Interestingly, a study examining differential serum metabolites showed significant alterations in the abundance of several metabolites among patients before and after surgery [61].”
BackgroundA methylation‐based mRNA signature predicts survival in patients with gastric cancer
Li, Y., Sun, R., Zhang, Y., Yuan, Y., & Miao, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01374-w · Cited by 8 · cited 1×
“Also, a study identifying methylated-differentially expressed genes (MDEGs) on a genome-wide scale systematically explored Multi-Omics cohorts from the TGCA and GEO to construct a new MDEGs-based signature [26].”
BackgroundGuo, H., Yang, J., Liu, S., Qin, T., Zhao, Q., Hou, X., & Ren, L. (2021) · Bioengineered · doi:10.1080/21655979.2021.1957645 · Cited by 7 · cited 1×
“Among them, CEMIP repressed the growth and migration and impaired the chemoresistance of GC cells to 5-FU, suggesting that CEMIP may be applied to precision medicine for GC patients [16].”
BackgroundPrognostic significance and immune characteristics of GPR27 in gastric cancer
Pan, J., & Gao, Y. (2023) · Aging · doi:10.18632/aging.205023 · Cited by 6 · cited 1×
“Recently, the expression profile of G-protein-coupled receptor 27 (GPR27) in GC was investigated based on TCGA and GEO database [31].”
MethodXu, J., Hu, S., Chen, Q., Shu, L., Wang, P., & Wang, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-41444-3 · Cited by 6 · cited 2×
“In particular, this study also found an association between TIME, (including monocytes, and neutrophils) and lncRNA-based ceRNA regulatory network [45].”
MethodResultExploring the Prognosis-Related Genetic Variation in Gastric Cancer Based on mGWAS
Zhang, Y., Lyu, Y., Chen, L., Cao, K., Chen, J., He, C., Lyu, X., Jiang, Y., Xiang, J., Liu, B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015259 · Cited by 5
Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases
Zhao, S., Wang, R., Song, S., Hao, D., Han, G., Song, X., Zhang, J., Pizzi, M. P., Shanbhag, N., Futreal, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106913 · Cited by 5 · cited 2×
“…LTF, CTAGE1, LAIR1, and HAVCR2, related to oncogenic, metabolic, and immune-related pathways, suggesting that combining proteomic and transcriptional analysis might result in a better understanding of the complex mechanisms affecting protein expression in peritoneal carcinomatosis from GC [91].”
BackgroundMethodLi, G., Huo, D., Guo, N., Li, Y., Ma, H., Liu, L., Xie, H., Zhang, D., Qu, B., & Chen, X. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1106724 · Cited by 5 · cited 1×
“2, and FLJ16779) [40].”
The regulatory roles and potential prognosis implications of long non-coding RNAs in gastric cancer.
Wang, Y., Yang, F., & Yang, Q. (2020) · PubMed · doi:10.14670/hh-18-188 · Cited by 4 · cited 1×
“However, accumulating evidence has found that ncRNAs contribute to the initiation and progression of GC and can act as important biomarkers in prognosis [35,36].”
Backgrounddos Santos, E. C., Rohan, P., Binato, R., & Abdelhay, E. (2023) · Cancers · doi:10.3390/cancers15225374 · Cited by 3 · cited 1×
“Another study examining intestinal GC molecular networks’ gene-microRNA relationship has shown that three regulatory circuits are identified in a complex interaction network [38].”
Background
Cited by
Applications and challenges of biomarker-based predictive models in proactive health management
Zhao, Q., Zhang, C., Zhang, W., Zhang, S., Liu, Q., & Guo, Y. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1633487 · Cited by 80
Beyond Biomarkers: Machine Learning-Driven Multiomics for Personalized Medicine in Gastric Cancer
Ma, D., Fan, C., Sano, T., Kawabata, K., Nishikubo, H., Imanishi, D., Sakuma, T., Maruo, K., Yamamoto, Y., Matsuoka, T., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050166 · Cited by 34
Self-citationMeng, X., Lang, Y., Li, X., Li, Y., Bu, Z., Wu, Y., & Zhang, S. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100639 · Cited by 12
Applications and advances of multi-omics technologies in gastrointestinal tumors
Liu, Y., Gao, F., Cheng, Y., Qi, L., & Yu, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1630788 · Cited by 16
Jin, Q., Chang, Z., Chen, K., Jiang, N., Chen, G., & Lu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690200 · Cited by 9
Metadata
- Authors
- Matsuoka, T., & Yashiro, M.
- Affiliations
- Osaka Metropolitan University (JP)
- Corresponding author
- Yashiro, Masakazu
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-05-28
- Volume
- 25
- Issue
- 11
- Pages
- 5880
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11172243
- OpenAlex
- W4399084028
- Cited by
- 83
- References
- 119
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 3
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- KAKENHI (Grant-in-Aid for Scientific Research) (21H03008)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- gastric cancer, prognostic factors, predictive biomarkers, multi-omics integration, epigenomics, transcriptomics, proteomics, metabolomics, genomics, biomarker discovery, therapeutic efficacy prediction, targeted therapy
- MeSH terms
- Humans, Prognosis, Stomach Neoplasms, Biomarkers, Tumor, Computational Biology, Genomics, Proteomics, Metabolomics, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.